UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September 25, 2013
POZEN INC.
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
000-31719
|
62-1657552
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
1414 Raleigh Road, Suite 400
Chapel Hill, North Carolina
|
27517
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
(919) 913-1030
|
|
(Registrant's telephone number, including area code)
|
|
Not applicable
|
||
|
(Former Name or Former Address, if Changed Since Last Report)
|
||
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
|
|
|
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On September 25, 2013, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of POZEN Inc. (the “Company”), approved one-time cash bonus awards for Elizabeth Cermak, the Company’s Executive Vice President and Chief Commercial Officer, in the amount of $90,000 and Gilda Thomas, the Company’s Senior Vice President and General Counsel, in the amount of $10,000, in recognition of their efforts in connection with the License and Collaboration Agreement recently entered into between the Company and sanofi-aventis U.S. LLC (“Sanofi”). Under the License Agreement, Sanofi will have responsibility for the commercialization of products containing a combination of immediate release omeprazole and 325 mg or less of delayed release aspirin, including PA32540 and PA8140, which are expected to be indicated for use for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers. In consideration for the rights granted to Sanofi under the License Agreement, Sanofi paid to POZEN an upfront payment of $15 million.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
POZEN Inc.
|
||
|
By:
|
/s/ William L. Hodges
|
|
|
Name:
|
William L. Hodges
|
|
|
Title:
|
Chief Financial Officer
|
|
Date: September 30, 2013
3